PALB2 and breast cancer: Among the triple-negative breast cancers, 22 were selected cases with a family history or bilateral breast cancers, the PALB2 mutation prevalence was 9.1 % (2/22), for 2 of four patients with deleterious mutations had triple-negative breast cancer, and had family history or bilateral breast cancer.